Evaluation of bivalirudin based anticoagulation for extracorporeal membrane oxygenation including patients with COVID-19

View Full Paper

Ask AI

Bookmark

Bivalirudin achieved timely therapeutic anticoagulation during ECMO, but COVID-19 patients had delayed results.
Median time to therapeutic activated partial thromboplastin time was 8.9 hours in pre-group, and 14.2 hours in post-group.
This retrospective analysis included adults on ECMO who received bivalirudin from 2015 to 2021, tracking outcomes pre- and post-protocol adjustments.
Standardized protocol shows promise, but longer adjustment times in COVID-19 patients highlight potential dosing challenges.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis evaluates bivalirudin efficacy in ECMO support, indicating safety concerns for COVID-19 patients.

Raguindin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark